Intended only for use by patients prescribed ▼Paxlovid (nirmatrelvir/ritonavir)® and carers of those patients in the United Kingdom.
Patient Information Website
Paxlovid is for the treatment of COVID-19 in adults 18 years of age and older with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalisation or death.
This website is not intended to replace the advice of your healthcare professional or to replace the advice in the Paxlovid Patient Information Leaflet, which is contained inside your medication package and should be consulted. If you have any questions about your medication, please speak to your doctor, nurse or pharmacist. Please refer to the Paxlovid Patient Information Leaflet for detailed information about your medicine.
Paxlovid is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.1
Paxlovid has a Conditional Marketing Authorisation (CMA)* in the United Kingdom.
*A Conditional Marketing Authorisation (CMA) means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.
Reporting Adverse Events:
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. This includes any possible side effects not listed in the package leaflet. If you get any side effects talk to your doctor, pharmacist or nurse. You can also report any side effects directly via the Coronavirus Yellow Card Reporting site https://coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
I am in:
References:
1. Paxlovid EMC Patient Information Leaflet (UK)
PP-C1D-GBR-0537. January 2025.